22 results
8-K
EX-10.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;
d. any and all claims for violation of any federal
8-K
EX-10.2
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
; false imprisonment; conversion; and disability benefits;
d. any and all claims for violation of any federal, state, or municipal statute, including
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
employment with us that is effected by us without “cause,” as defined in the Severance Plan (and other than due to death or disability), or (b)
a resignation … (a) a termination of an eligible participant’s employment with us that is effected by us without “cause” (and other than due to death or disability
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
to disability and a devastating impact on quality of life.
Izokibep has advanced to Phase 3 development in moderate-to-severe HS. In September 2023 … parameters: (a) patient global assessment of disease activity; (b) physician global assessment of disease activity; (c) patient pain scale; (d) disability
8-K
EX-99.2
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
glands and is typically accompanied by pain, malodor, drainage, and disfigurement that contribute to disability and a devastating impact on quality … of life. Patients with HS miss a greater number of days of work and have increased disability compared to the average population. In 2019, there were
8-K
EX-99.3
ut9y4z5d
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
qhygj 6mgonwqbl
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
EX-10.1
ba9qehds4dsh8b2
2 Aug 23
Departure of Directors or Certain Officers
5:05pm
8-K
EX-3.2
y0irw fjjath02
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
424B4
q0nfs 9vxxuilatonvi
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
yneoys
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-3.4
krivc5dy9z
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.4
11sx1mlndygwqb dg5
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.9
m5sbmac7yx7
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.3
g7jo450yijgd qxe
1 May 23
IPO registration (amended)
6:10am
S-1
gg6p5ygo2wwnhp1
13 Apr 23
IPO registration
5:10pm
S-1
EX-3.3
trw6imx8078qae2
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.1
fqsxwy0wx1 8dmvrzh
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
hyp3v7pp43pwd
13 Apr 23
IPO registration
5:10pm